Respiri's (ASX:RSH) patient programs showed a "significant" reduction in hospitalizations and emergency room visits, accelerating discussions with new and existing clients, according to a Friday filing with the Australian bourse.
The programs registered a 56% decline in rehospitalizations and a 47% drop in emergency room visits.
The medical devices company is in advanced contract discussions with new potential clients as it increases revenues for existing partner Ceras' clients by 51%, to $74 from around $49 per patient per month, and increased the number of monthly reimbursed services to patients to 1.4 from around 1, the filing stated.
The company's shares jumped 5% in recent Monday trade.
Price (AUD): $0.04, Change: $+0.002, Percent Change: +5.00%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。